Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Labortory focus was changed and study was not opened at all
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The role of alpha2 receptor agonist on pain perception and modulation will be examined. In addition whether this is mediated through the opioid system will be examined. Pain perception and modulation will be examined before and after administration of Clonidine or placebo together with Naloxone or saline.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Clonidine+ Saline | Active Comparator | Clonidine 0.15 mg and saline 0.15 mg/kg |
|
| Clonidine + Naloxone | Active Comparator | Clonidine 0.15 mg and Naloxone 0.15 mg/kg |
|
| Placebo +Naloxone | Active Comparator | Placebo 0.15 mg+ naloxone 0.15 mg/kg |
|
| Placebo +saline | Placebo Comparator | Placebo 0.15 mg+ saline 0.15 mg/kg |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Clonidine | Drug | Clonidine 0.15 mg |
| |
| Measure | Description | Time Frame |
|---|---|---|
| The changes in pain responses after administration of alpha 2 agonist and mu receptor antagonist | The change in pain perception (pain thresholds and pain ratings of suprathresholds stimuli) and in the excitatory and inhibitory pain modulation responses (assessed by the temporal summation and conditioned pain modulation paradigms) will be examined before and after administration of alpha 2 agonist with and without mu receptor antagonist | 2 years |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Rambam Health Care Campus | Haifa | Israel |
Not provided
| ID | Term |
|---|---|
| D003000 | Clonidine |
| D009270 | Naloxone |
| D012965 | Sodium Chloride |
| ID | Term |
|---|---|
| D048288 | Imidazolines |
| D007093 | Imidazoles |
| D001393 | Azoles |
| D006573 | Heterocyclic Compounds, 1-Ring |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Naloxone |
| Drug |
naloxone 0.15 mg/kg |
|
| placebo | Drug |
|
| saline | Other |
|
| D006571 |
| Heterocyclic Compounds |
| D009019 | Morphinans |
| D053610 | Opiate Alkaloids |
| D000470 | Alkaloids |
| D006572 | Heterocyclic Compounds, Bridged-Ring |
| D006576 | Heterocyclic Compounds, 4 or More Rings |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D010616 | Phenanthrenes |
| D011084 | Polycyclic Aromatic Hydrocarbons |
| D011083 | Polycyclic Compounds |
| D002712 | Chlorides |
| D006851 | Hydrochloric Acid |
| D017606 | Chlorine Compounds |
| D007287 | Inorganic Chemicals |
| D017670 | Sodium Compounds |